Wedbush reiterated their outperform rating on shares of Fennec Pharmaceuticals (NASDAQ:FENC – Get Rating) in a research report released on Wednesday, Marketbeat reports. The brokerage currently has a $11.00 price objective on the stock.
Several other equities analysts also recently issued reports on the stock. Capital One Financial initiated coverage on shares of Fennec Pharmaceuticals in a research note on Wednesday, September 7th. They set an overweight rating and a $11.00 price target for the company. Craig Hallum reaffirmed a buy rating and set a $14.00 price target on shares of Fennec Pharmaceuticals in a research note on Monday, August 8th. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat.com, Fennec Pharmaceuticals presently has an average rating of Moderate Buy and an average price target of $11.50.
Fennec Pharmaceuticals Price Performance
Shares of NASDAQ:FENC opened at $8.54 on Wednesday. The company has a market cap of $222.71 million, a price-to-earnings ratio of -12.75 and a beta of 0.09. The company has a debt-to-equity ratio of 0.47, a current ratio of 5.12 and a quick ratio of 5.12. The firm has a 50 day simple moving average of $6.86 and a 200 day simple moving average of $6.16. Fennec Pharmaceuticals has a one year low of $3.82 and a one year high of $8.75.
Institutional Investors Weigh In On Fennec Pharmaceuticals
A hedge fund recently raised its stake in Fennec Pharmaceuticals stock. JPMorgan Chase & Co. boosted its stake in Fennec Pharmaceuticals Inc (NASDAQ:FENC – Get Rating) by 23,280.0% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 16,366 shares of the company’s stock after purchasing an additional 16,296 shares during the quarter. JPMorgan Chase & Co. owned about 0.06% of Fennec Pharmaceuticals worth $91,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 43.29% of the company’s stock.
About Fennec Pharmaceuticals
Fennec Pharmaceuticals Inc, a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children.
- Get a free copy of the StockNews.com research report on Fennec Pharmaceuticals (FENC)
- The Worst May be Over for Target, But is the Stock Safe to Buy?
- Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?
- Two Fun Stocks The Insiders Are Buying
- Novavax Remains a Risk-On Stock in a Risk-Off Market
- 3 Defensive Stocks With 60-Year Dividend Hike Streaks
Receive News & Ratings for Fennec Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fennec Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.